We are live on ! Find out more
DYN icon

Dyne Therapeutics
DYN

114 hedge funds and large institutions have $537M invested in Dyne Therapeutics in 2023 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 47 increasing their positions, 32 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

3,615% more call options, than puts

Call options by funds: $3.05M | Put options by funds: $82K

47% more repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 32

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

3.36% less ownership

Funds ownership: 101.51% → 98.15% (-3.4%)

3% less funds holding

Funds holding: 118 → 114 (-4)

19% less capital invested

Capital invested by funds: $666M → $537M (-$129M)

29% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 14

Holders
114
Holders Change
-4
Holders Change %
-3.39%
% of All Funds
1.81%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
10
Increased
47
Reduced
32
Closed
14
Calls
$3.05M
Puts
$82K
Net Calls
+$2.96M
Net Calls Change
+$3.1M

Top Buyers

1
VC
Vivo Capital
California
+$4.93M
2
B
Braidwell
Connecticut
+$4.78M
3
LGM
Logos Global Management
California
+$4.31M
4
Citadel Advisors
Citadel Advisors
Florida
+$3.61M
5
JP Morgan Chase
JP Morgan Chase
New York
+$3.26M

Top Sellers

1
EC
EcoR1 Capital
California
-$8.99M
2
WA
Wasatch Advisors
Utah
-$6.16M
3
PCH
Polar Capital Holdings
United Kingdom
-$5.63M
4
Goldman Sachs
Goldman Sachs
New York
-$5.4M
5
Norges Bank
Norges Bank
Norway
-$2.2M
Name Holding Trade Value Shares
Change 		Change in
Stake
NCM
26
Nantahala Capital Management
Connecticut
$6.12M +$969K +90,000 +15%
Point72 Asset Management
27
Point72 Asset Management
Connecticut
$5.16M +$1.59M +147,271 +34%
Ensign Peak Advisors
28
Ensign Peak Advisors
Utah
$4.58M – – –
Axa
29
Axa
France
$4.27M -$18.4K -1,704 -0.4%
Northern Trust
30
Northern Trust
Illinois
$3.53M +$144K +13,323 +3%
ACH
31
ArrowMark Colorado Holdings
Colorado
$3.43M – – –
JP Morgan Chase
32
JP Morgan Chase
New York
$3.03M +$3.26M +302,562 +850%
WP
33
Woodline Partners
California
$3.01M -$503K -46,692 -12%
Charles Schwab
34
Charles Schwab
California
$2.92M +$434K +40,250 +14%
ACM
35
Altium Capital Management
New York
$2.82M +$1.72M +160,000 +103%
Walleye Capital
36
Walleye Capital
New York
$2.51M +$3.02M +280,276 New
AllianceBernstein
37
AllianceBernstein
Tennessee
$2.25M -$1.24M -114,839 -31%
ECM
38
ExodusPoint Capital Management
New York
$1.65M +$1.61M +149,526 +434%
T. Rowe Price Associates
39
T. Rowe Price Associates
Maryland
$1.57M +$1.77M +164,444 +1,503%
AG
40
Algert Global
California
$1.42M -$866K -80,359 -34%
Bank of New York Mellon
41
Bank of New York Mellon
New York
$1.41M +$77.5K +7,196 +5%
N
42
Nuveen
North Carolina
$1.32M -$11.8K -1,097 -0.7%
Russell Investments Group
43
Russell Investments Group
United Kingdom
$1.32M +$386K +35,842 +32%
ACP
44
Acuta Capital Partners
California
$1.31M +$792K +73,500 +101%
Rafferty Asset Management
45
Rafferty Asset Management
New York
$1.25M +$239K +22,145 +19%
IBT
46
International Biotechnology Trust
United Kingdom
$1.23M -$1.76M -163,000 -54%
Wellington Management Group
47
Wellington Management Group
Massachusetts
$1.04M +$57.9K +5,371 +5%
UOC
48
UBS O'Connor
Illinois
$992K -$700K -65,000 -37%
Morgan Stanley
49
Morgan Stanley
New York
$965K -$76.5K -7,103 -6%
Barclays
50
Barclays
United Kingdom
$892K +$190K +17,603 +21%
1
2
3 4 5

DYN Hedge Fund Activity: Q3 2023 in Review

114 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Dyne Therapeutics (DYN) for Q3 2023, worth a combined $537M — down 19% from $666M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of DYN and 10 opened new positions — a net loss of 4 holders — while 32 trimmed existing stakes and 47 added.

The largest buyer was Vivo Capital, adding an estimated $4.93M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $8.99M sold.

  • 114 institutional investors held Dyne Therapeutics (DYN) as of Q3 2023, down from 118 in Q2 2023.
  • Funds reported $537M of Dyne Therapeutics stock for Q3 2023, down 19% quarter-over-quarter.
  • 10 funds opened new Dyne Therapeutics positions in Q3 2023 and 14 closed out, a net change of -4 holders.
  • The largest Dyne Therapeutics buyer in Q3 2023 was Vivo Capital, an estimated $4.93M added.
  • The largest Dyne Therapeutics seller in Q3 2023 was EcoR1 Capital, an estimated $8.99M sold.

Based on aggregated 13F filings for Q3 2023.